Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Fennec Pharmaceuticals Inc. (T:FRX)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
Company Contact
Address: 68 Tw Alexander Dr
PO Box 13628
Tel: N/A
IR: See website
Key People
Rostislav C. Raykov
Chief Executive Officer, Director
Robert C. Andrade
Chief Financial Officer
Adrian J. Haigh
Chief Operating Officer
Business Overview
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company, which is focused on its product candidate PEDMARK. The Company sells its product through a field force, including regional pediatric oncology specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration (FDA) approved therapy indicates to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic and solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.
Financial Overview
For the nine months ended 30 September 2023, Fennec Pharmaceuticals Inc revenues increased from $0K to $11.5M. Net loss decreased 21% to $13.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development decrease of 99% to $24K (expense), Interest income increase from $42K to $326K (income).
Employees: 36 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $313.66M as of Sep 30, 2023
Annual revenue (TTM): $17.74M as of Sep 30, 2023
EBITDA (TTM): -$23.22M as of Sep 30, 2023
Net annual income (TTM): -$27.48M as of Sep 30, 2023
Free cash flow (TTM): -$25.93M as of Sep 30, 2023
Net Debt Last Fiscal Year: $17.12M as of Sep 30, 2023
Shares outstanding: 26,634,676 as of Nov 3, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization